ORION CORP.B UNSP.ADR 1/2 (OFK0) - Net Assets
Based on the latest financial reports, ORION CORP.B UNSP.ADR 1/2 (OFK0) has net assets worth €- EUR (≈ $- USD) as of . Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€- ≈ $- USD) and total liabilities (€- ≈ $- USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
ORION CORP.B UNSP.ADR 1/2 - Net Assets Trend (None–None)
This chart illustrates how ORION CORP.B UNSP.ADR 1/2's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for ORION CORP.B UNSP.ADR 1/2 (None–None)
The table below shows the annual net assets of ORION CORP.B UNSP.ADR 1/2 from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to ORION CORP.B UNSP.ADR 1/2's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
ORION CORP.B UNSP.ADR 1/2 Competitors by Market Cap
The table below lists competitors of ORION CORP.B UNSP.ADR 1/2 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
SAINSBURY -J.- ADR/4 NEW
F:SUY
|
$8.31 Billion |
|
Baiyin Nonferrous Group Co Ltd
SHG:601212
|
$8.31 Billion |
|
Keyera Corp.
TO:KEY
|
$8.31 Billion |
|
Procore Technologies Inc
NYSE:PCOR
|
$8.32 Billion |
|
Krafton Inc
KO:259960
|
$8.30 Billion |
|
Mineral Resources Ltd
AU:MIN
|
$8.30 Billion |
|
Zoomlion Heavy Industry Science and Technology Co Ltd
SHE:000157
|
$8.30 Billion |
|
GETLINK ADR EO-40
F:TNU
|
$8.29 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in ORION CORP.B UNSP.ADR 1/2's equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares ORION CORP.B UNSP.ADR 1/2's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently ORION CORP.B UNSP.ADR 1/2 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares ORION CORP.B UNSP.ADR 1/2's net assets metrics with peer companies in the Drug Manufacturers - General industry.
Industry Context
- Industry: Drug Manufacturers - General
- Average net assets among peers: $26,297,067,571
- Average return on equity (ROE) among peers: 8.12%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| ORION CORP.B UNSP.ADR 1/2 (OFK0) | €- | N/A | N/A | $8.31 Billion |
| Bayer AG NA (BAYN) | $33.17 Billion | 3.01% | 2.63x | $44.22 Billion |
| Cosmo Pharmaceuticals N.V (C43) | $489.18 Million | -0.74% | 0.25x | $1.65 Billion |
| CSPC Pharmaceutical Group Limited (CVG) | $31.64 Billion | 19.25% | 0.32x | $10.18 Billion |
| CSPC PHARMACEUT.GR. ADR4 (CVGU) | $31.64 Billion | 19.25% | 0.32x | $11.04 Billion |
| Grifols S.A (G0FB) | $8.46 Billion | 2.46% | 1.55x | $2.02 Billion |
| Sanofi (SNW2) | $59.03 Billion | 7.29% | 0.89x | $105.72 Billion |
| AstraZeneca PLC (ZEGA) | $19.65 Billion | 6.28% | 1.98x | $252.57 Billion |
About ORION CORP.B UNSP.ADR 1/2
Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. The company provides pharmaceutical products, which includes Nubeqa for the treatment of prostate cancer; Entacapone, Stalevo, Comtess, and Comtan to treat Parkinson's disease; Burana for inflam… Read more